Our promising new cancer drug
Breakthrough Breast Cancer has an amazing record in getting new drugs into clinical trials, with 10 new treatments into clinical trials in the past 10 years. One of those is a genuinely pioneering drug called olaparib which is being hailed by experts as a new direction in cancer treatment.
The drug has been developed to combat specific forms of hereditary breast and ovarian cancer. And this week breast and ovarian cancer trial results have been published in the prestigious journal, The Lancet. The trials’ results are very promising and show that in women who have had many different types of chemotherapy, the drug shrank tumours in about 40% of cases. And due to the targeted nature of the drug, it caused few side effects.
As always, none of this would have been possible without your support. Your generosity continues to help our scientists in the fight against breast cancer. It is incredibly exciting to see the work we have done in the labs become a reality in clinical trials. Our vision of ‘a future free from the fear of breast cancer’ is not only an aspiration but is fast becoming an achievable reality.
